Survey: EU physicians still face learning curve for biosimilars
By Mari Serebrov
Tuesday, March 18, 2014
Biosimilar makers have their work cut out for them if they hope to increase the use of their follow-on biologics in Europe. Much of that work is in helping doctors over the learning curve.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.